Hematological Malignancies

90 Y Ibritumomab tiuxetan : Active in Chemorefractory NHL

20 40 60 80 100

Randomized Phase 3 Trial

83%

73%

71%

42%

ZEVALIN ( n =35)

ZEVALIN ( n =33)

Rituxan ( n =35)

Rituxan ( n =31)

International Workshop Response Criteria (%) 0

Chemorefractory P = 0.022

Chemosensitive P = 0.394